GlycoMimetics Inc (GLYC):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9814)
◆英語タイトル:GlycoMimetics Inc (GLYC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9814
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:55
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
GlycoMimetics Inc (GlycoMimetics) is a clinical-stage biotechnology company that research, develops and commercializes small molecule drugs. The company’s products comprise rivipansel (GMI-1070), under phase III clinical trial is an anti-inflammatory compound to treat vaso-occlusive crisis of sickle cell disease and blood cancers. It also provides GMI-1271, galectin inhibitors, GMI – 1359, GMI-1051 and research programs. GlycoMimetics designs and tests viral and bacterial entry inhibitors dendritic cell receptor. The company uses proprietary glycobiology technology to develop treatments for diseases. It also offers clinical research programs. GlycoMimetics is headquartered in Rockville, Maryland, the US.

GlycoMimetics Inc (GLYC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GlycoMimetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
IAVI, GlycoMimetics, And Glycosensors and Diagnostics Enter Into Agreement To Develop AIDS Vaccine 11
Equity Offering 12
GlycoMimetics Prices Public Offering of Shares for USD119 Million 12
GlycoMimetics Raises USD92.6 Million in Public Offering of Shares 14
GlycoMimetics Raises USD21 Million in Public Offering of Shares 16
GlycoMimetics Raises USD3 Million in First Tranche of Public Offering of Shares 18
GlycoMimetics Completes IPO For US$64.4 Million 19
GlycoMimetics Inc – Key Competitors 21
GlycoMimetics Inc – Key Employees 22
GlycoMimetics Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Nov 02, 2018: GlycoMimetics reports third quarter 2018 results and highlights recent company achievements 24
Aug 09, 2018: Glycomimetics reports second quarter 2018 results and highlights recent company achievements 26
May 03, 2018: GlycoMimetics Reports First Quarter 2018 Results 27
Mar 06, 2018: GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results 28
Nov 08, 2017: GlycoMimetics Reports Program Updates and Third Quarter 2017 Results 29
Aug 03, 2017: GlycoMimetics Reports Program Updates and Second Quarter 2017 Results 31
May 08, 2017: GlycoMimetics Reports Program Updates and First Quarter 2017 Results 33
Mar 01, 2017: GlycoMimetics Reports Fourth Quarter and Year-End 2016 Results 34
Corporate Communications 35
Jun 12, 2017: GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors 35
Mar 13, 2017: GlycoMimetics Appoints Scott Koenig of MacroGenics to Board of Directors 36
Product News 37
06/05/2017: GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting 37
05/17/2017: GlycoMimetics’ GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia 38
Product Approvals 39
May 25, 2017: GlycoMimetics’ GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia 39
Clinical Trials 40
May 30, 2018: GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy 40
Mar 14, 2018: GlycoMimetics to Present New Preclinical Data for GMI-1271 at AACR Annual Meeting 2018 41
Mar 14, 2018: GlycoMimetics to Present New Preclinical Data for GMI-1359 at AACR Annual Meeting 2018 42
Mar 05, 2018: GlycoMimetics Announces Design of Phase 3 Clinical Trial for GMI-1271 in Relapsed/Refractory AML 43
Feb 08, 2018: GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Chemotherapy 44
Dec 12, 2017: GlycoMimetics Reports Improvements in Median Overall Survival Versus Historical Matched Controls for Two AML Patient Subgroups in Phase 1/2 Trial for GMI-1271 45
Nov 01, 2017: GlycoMimetics to Highlight GMI-1271 Clinical Data and Underlying, Differentiated Mechanism of Action in Oral Presentations at 59th Annual ASH Meeting 46
May 18, 2017: GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML 48
May 02, 2017: GlycoMimetics Announces Publication of Preclinical Data Showing Role of E-selectin Ligands in Multiple Myeloma 50
Apr 20, 2017: GlycoMimetics to Present New AML Clinical Data at ASCO 2017 Annual Meeting 51
Mar 07, 2017: GlycoMimetics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271 52
Mar 02, 2017: GlycoMimetics to Present New Preclinical Data of GMI-1271 at AACR Annual Meeting 2017 53
Mar 02, 2017: GlycoMimetics to Present New Preclinical Data of GMI-1359 at AACR Annual Meeting 2017 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GlycoMimetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GlycoMimetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
IAVI, GlycoMimetics, And Glycosensors and Diagnostics Enter Into Agreement To Develop AIDS Vaccine 11
GlycoMimetics Prices Public Offering of Shares for USD119 Million 12
GlycoMimetics Raises USD92.6 Million in Public Offering of Shares 14
GlycoMimetics Raises USD21 Million in Public Offering of Shares 16
GlycoMimetics Raises USD3 Million in First Tranche of Public Offering of Shares 18
GlycoMimetics Completes IPO For US$64.4 Million 19
GlycoMimetics Inc, Key Competitors 21
GlycoMimetics Inc, Key Employees 22

List of Figures
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ GlycoMimetics Inc (GLYC):製薬・医療:M&Aディール及び事業提携情報(GlycoMimetics Inc (GLYC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆